Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase NA 4Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 4Active not recruiting 4Recruiting 3Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 145Carcinoma, Non-Small-Cell Lung 97Colorectal Neoplasms 96Carcinoma, Hepatocellular 69Stomach Neoplasms 65Rectal Neoplasms 54Neoplasms 53Lung Neoplasms 44Prostatic Neoplasms 41Colonic Neoplasms 41Leukemia, Myeloid, Acute 40Nasopharyngeal Carcinoma 39Lymphoma, Large B-Cell, Diffuse 39Uterine Cervical Neoplasms 37Esophageal Neoplasms 33Ovarian Neoplasms 32Neoplasm Metastasis 32Multiple Myeloma 31Lymphoma 31Lymphoma, Follicular 30Leukemia 28Pancreatic Neoplasms 27Recurrence 23Head and Neck Neoplasms 22Brain Neoplasms 21Urinary Bladder Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Non-Hodgkin 19Lymphoma, Mantle-Cell 18Squamous Cell Carcinoma of Head and Neck 17

Interventions

Thalidomide 1Dexamethasone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Pathologic Complete Response × Clear all
NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡